Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011

Phase 1

Completed

Conditions: Normal Hepatic Function
Impaired Hepatic Function

Interventions: Drug: LEE011

First Posted Date: 2015-03-17

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT02388620

Locations: 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
University of Miami, Coral Gables, Florida, United States

Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)

Conditions: Heart Failure With Reduced Ejection Fraction (HF-rEF)

First Posted Date: 2015-03-17

Last Posted Date: 2021-02-15

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT02389933

Locations: 🇦🇪
Novartis Investigative Site, Ras Al Khaimah, United Arab Emirates

CINC424A2X01B Rollover Protocol

Phase 4

Active, not recruiting

Conditions: Primary Myelofibrosis
Polycythemia Vera
Thalassemia
Acute Myeloid Leukemia
Graft Versus Host Disease

Interventions: Drug: ruxolitinib
Drug: panobinostat

First Posted Date: 2015-03-12

Last Posted Date: 2025-05-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 356

Registration Number: NCT02386800

Locations: 🇹🇷
Novartis Investigative Site, Talas Kayseri, Turkey

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

Phase 1

Active, not recruiting

Conditions: Advanced Malignancies That Harbor IDHR132 Mutations

Interventions: Drug: IDH305

First Posted Date: 2015-03-06

Last Posted Date: 2025-03-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 166

Registration Number: NCT02381886

Locations: 🇺🇸
Uni Of TX MD Anderson Cancer Cntr, Houston, Texas, United States
🇺🇸
Dana Farber Cancer Institute SC (1), Boston, Massachusetts, United States
🇺🇸
Columbia University Medical Center- New York Presbyterian Onc Dept., New York, New York, United States

and more 2 locations

RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity

Phase 3

Completed

Conditions: Retinopathy of Prematurity

Interventions: Drug: Ranibizumab
Procedure: Laser therapy

First Posted Date: 2015-03-03

Last Posted Date: 2018-11-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 224

Registration Number: NCT02375971

Locations: 🇬🇧
Novartis Investigative Site, Portsmouth, United Kingdom

PCA062 in pCAD-positive Tumors.

Phase 1

Completed

Conditions: Triple Negative Breast Cancer
Head & Neck Cancer
Esophageal Cancer

Interventions: Drug: PCA062

First Posted Date: 2015-03-03

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 47

Registration Number: NCT02375958

Locations: 🇪🇸
Novartis Investigative Site, Madrid, Spain

A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: osilodrostat

First Posted Date: 2015-02-26

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 33

Registration Number: NCT02372084

Locations: 🇺🇸
University of Miami / Clinical Research Services, Inc. Boynton Beach, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States

Fingolimod Effect on Cytokine and Chemokine Levels

Phase 4

Completed

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: Fingolimod 0.5 mg

First Posted Date: 2015-02-26

Last Posted Date: 2019-09-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 126

Registration Number: NCT02373098

Locations: 🇹🇷
Novartis Investigative Site, Istanbul, Turkey

A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD

Phase 4

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: NVA237
Drug: Placebo
Drug: Salbutamol

First Posted Date: 2015-02-25

Last Posted Date: 2019-08-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 776

Registration Number: NCT02371629

Locations: 🇸🇪
Novartis Investigative Site, Lund, Sweden

Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis

Phase 1

Completed

Conditions: Myelofibrosis

Interventions: Drug: PIM447
Drug: Ruxolitinib
Drug: LEE011

First Posted Date: 2015-02-25

Last Posted Date: 2022-02-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 15

Registration Number: NCT02370706

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy